208 related articles for article (PubMed ID: 28155899)
1. Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.
Friess J; Hecker M; Roch L; Koczan D; Fitzner B; Angerer IC; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Zettl UK
Sci Rep; 2017 Feb; 7():42087. PubMed ID: 28155899
[TBL] [Abstract][Full Text] [Related]
2. High-Resolution Expression Profiling of Peripheral Blood CD8
Roch L; Hecker M; Friess J; Angerer IC; Koczan D; Fitzner B; Schröder I; Flechtner K; Thiesen HJ; Meister S; Winkelmann A; Zettl UK
Mol Neurobiol; 2017 Sep; 54(7):5511-5525. PubMed ID: 27631876
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Muls N; Dang HA; Sindic CJ; van Pesch V
PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
[TBL] [Abstract][Full Text] [Related]
6. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients.
Huber JE; Chang Y; Meinl I; Kümpfel T; Meinl E; Baumjohann D
J Immunol; 2020 Mar; 204(5):1101-1110. PubMed ID: 32034063
[TBL] [Abstract][Full Text] [Related]
8. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
[TBL] [Abstract][Full Text] [Related]
10. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Immunol; 2018; 9():2669. PubMed ID: 30524432
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
Haas J; Schwarz A; Korporal-Kunke M; Jarius S; Wiendl H; Kieseier BC; Wildemann B
Mult Scler; 2015 Oct; 21(12):1521-32. PubMed ID: 25583847
[TBL] [Abstract][Full Text] [Related]
12. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Henault D; Galleguillos L; Moore C; Johnson T; Bar-Or A; Antel J
Neurology; 2013 Nov; 81(20):1768-72. PubMed ID: 24132373
[TBL] [Abstract][Full Text] [Related]
13. Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
Fujii C; Kondo T; Ochi H; Okada Y; Hashi Y; Adachi T; Shin-Ya M; Matsumoto S; Takahashi R; Nakagawa M; Mizuno T
Sci Rep; 2016 Oct; 6():35314. PubMed ID: 27752051
[TBL] [Abstract][Full Text] [Related]
14. Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.
Yokoseki A; Saji E; Arakawa M; Hokari M; Ishiguro T; Yanagimura F; Ishihara T; Okamoto K; Nishizawa M; Kawachi I
Mult Scler; 2013 Aug; 19(9):1230-3. PubMed ID: 23519973
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
[TBL] [Abstract][Full Text] [Related]
16. Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling.
Sacco R; Emming S; Gobbi C; Zecca C; Monticelli S
Mult Scler Relat Disord; 2020 May; 40():101927. PubMed ID: 31931457
[TBL] [Abstract][Full Text] [Related]
17. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patients.
Sferruzza G; Clarelli F; Mascia E; Ferrè L; Ottoboni L; Sorosina M; Santoro S; Filippi M; Provero P; Esposito F
Pharmacogenomics; 2022 Feb; 23(3):161-171. PubMed ID: 35068175
[No Abstract] [Full Text] [Related]
19. Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy.
Koczan D; Fitzner B; Zettl UK; Hecker M
Sci Data; 2018 Jul; 5():180145. PubMed ID: 30040082
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod-Associated Peripheral Vascular Adverse Effects.
Russo M; Guarneri C; Mazzon E; Sessa E; Bramanti P; Calabrò RS
Mayo Clin Proc; 2015 Oct; 90(10):1424-7. PubMed ID: 26349949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
